APP and Alzheimer disease: However, a study published in 2023 investigated whether the novel glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist DA4-JC provided protective effects in the triple APP/PS1/tau mouse model of AD using in vivo LTP recordings of the hippocampus, biochemical analyses of biomarkers, and quantified synapses using the Golgi method.